Severe hyperglycemia following transition from octreotide to lanreotide in a patient with enterocutaneous fistula receiving parenteral nutrition
| Autor: | Abbie N. Rosen, Julia Balazh, Andrew J. Franck |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Enterocutaneous fistula
Parenteral Nutrition medicine.medical_specialty endocrine system diseases Medicine (miscellaneous) Octreotide Lanreotide Peptides Cyclic Gastroenterology chemistry.chemical_compound Internal medicine Diabetes mellitus Diabetes Mellitus Intestinal Fistula Humans Medicine Nutrition and Dietetics business.industry nutritional and metabolic diseases medicine.disease Somatostatin Analogue Parenteral nutrition Somatostatin chemistry Hyperglycemia business medicine.drug |
| Zdroj: | Nutrition in Clinical Practice. 37:727-731 |
| ISSN: | 1941-2452 0884-5336 |
| DOI: | 10.1002/ncp.10757 |
| Popis: | Somatostatin analogues, suchas octreotide and lanreotide, are commonly used in the management of enterocutaneous fistula. We report a case of severe and prolonged hyperglycemia that occurred in a patient after receiving a one-time dose of lanreotide, who had previously been stable on octreotide and did not have a history of diabetes mellitus. Management of the patient's hyperglycemia while receiving parenteral nutrition is described. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text